

# World Journal of *Virology*

*World J Virol* 2022 July 25; 11(4): 170-220



**MINIREVIEWS**

- 170 COVID-19 vaccination and myocarditis: A review of current literature  
*Dhaduk K, Khosla J, Hussain M, Mangaroliya V, Chauhan S, Ashish K, Gupta R, Pal S*
- 176 Air leaks in COVID-19  
*Juneja D, Kataria S, Singh O*

**SYSTEMATIC REVIEWS**

- 186 COVID-19 pandemic effects on the distribution of healthcare services in India: A systematic review  
*Nimavat N, Hasan MM, Charmode S, Mandala G, Parmar GR, Bhangu R, Khan I, Singh S, Agrawal A, Shah A, Sachdeva V*

**CASE REPORT**

- 198 COVID-19 presenting with persistent hiccup and myocardial infarction in a peritoneal dialysis patient: A case report  
*Bacharaki D, Giannakopoulos P, Markakis K, Papas C, Theodorou A, Zoi V, Tsivgoulis G, Lionaki S*

**LETTER TO THE EDITOR**

- 204 Management of SARS-CoV-2 infection is a major challenge in patients with lymphoid malignancies: Warrants a clear therapeutic strategy  
*Sahu T, Verma HK, Lvks B*
- 208 Chemsex and its risk factors associated with human immunodeficiency virus among men who have sex with men in Hong Kong  
*Chan ASW, Tang PMK, Yan E*
- 212 Cautious optimism in anticipation of hepatitis B curative therapies  
*Turshudzhyan A, Tadros M*
- 216 "Heart failure in COVID-19 patients: Critical care experience": A letter to the editor  
*Tsigkou V, Siasos G, Oikonomou E, Bletsas E, Vavuranakis M, Tousoulis D*

**ABOUT COVER**

Editorial Board Member of *World Journal of Virology*, Shahid Akhtar Siddiqui, MBBS, MD, Assistant Professor, Doctor, Department of Pediatrics, MLN Medical College, King George Medical University, Lucknow, Allahabad 211002, Uttar Pradesh, India. sha.akht@yahoo.com

**AIMS AND SCOPE**

The primary aim of *World Journal of Virology (WJV, World J Virol)* is to provide scholars and readers from various fields of virology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

*WJV* mainly publishes articles reporting research results obtained in the field of virology and covering a wide range of topics including arbovirus infections, viral bronchiolitis, central nervous system viral diseases, coinfection, DNA virus infections, viral encephalitis, viral eye infections, chronic fatigue syndrome, animal viral hepatitis, human viral hepatitis, viral meningitis, opportunistic infections, viral pneumonia, RNA virus infections, sexually transmitted diseases, viral skin diseases, slow virus diseases, tumor virus infections, viremia, and zoonoses.

**INDEXING/ABSTRACTING**

The *WJV* is now abstracted and indexed in PubMed, PubMed Central, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database.

**RESPONSIBLE EDITORS FOR THIS ISSUE**

Production Editor: *Yu-Xi Chen*; Production Department Director: *Xiang Li*; Editorial Office Director: *Jin-Lai Wang*.

**NAME OF JOURNAL**

*World Journal of Virology*

**ISSN**

ISSN 2220-3249 (online)

**LAUNCH DATE**

February 12, 2012

**FREQUENCY**

Bimonthly

**EDITORS-IN-CHIEF**

Mahmoud El-Bendary, En-Qiang Chen

**EDITORIAL BOARD MEMBERS**

<https://www.wjgnet.com/2220-3249/editorialboard.htm>

**PUBLICATION DATE**

July 25, 2022

**COPYRIGHT**

© 2022 Baishideng Publishing Group Inc

**INSTRUCTIONS TO AUTHORS**

<https://www.wjgnet.com/bpg/gerinfo/204>

**GUIDELINES FOR ETHICS DOCUMENTS**

<https://www.wjgnet.com/bpg/GerInfo/287>

**GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH**

<https://www.wjgnet.com/bpg/gerinfo/240>

**PUBLICATION ETHICS**

<https://www.wjgnet.com/bpg/GerInfo/288>

**PUBLICATION MISCONDUCT**

<https://www.wjgnet.com/bpg/gerinfo/208>

**ARTICLE PROCESSING CHARGE**

<https://www.wjgnet.com/bpg/gerinfo/242>

**STEPS FOR SUBMITTING MANUSCRIPTS**

<https://www.wjgnet.com/bpg/GerInfo/239>

**ONLINE SUBMISSION**

<https://www.f6publishing.com>

## Cautious optimism in anticipation of hepatitis B curative therapies

Alla Turshudzhyan, Micheal Tadros

**Specialty type:** Gastroenterology and hepatology

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review report's scientific quality classification**

Grade A (Excellent): 0  
Grade B (Very good): B  
Grade C (Good): C, C, C  
Grade D (Fair): 0  
Grade E (Poor): 0

**P-Reviewer:** Chi G, China; Gao P, China; Morozov S, Russia; Sira AM, Egypt

**Received:** February 19, 2022

**Peer-review started:** February 19, 2022

**First decision:** May 12, 2022

**Revised:** May 15, 2022

**Accepted:** July 16, 2022

**Article in press:** July 16, 2022

**Published online:** July 25, 2022



**Alla Turshudzhyan**, Department of Medicine, University of Connecticut, Farmington, CT 06030-1235, United States

**Micheal Tadros**, Department of Gastroenterology and Hepatology, Albany Medical College, Albany, NY 12208, United States

**Corresponding author:** Alla Turshudzhyan, DO, Department of Medicine, University of Connecticut, 263 Farmington Avenue, Farmington, CT 06030-1235, United States.  
[turshudzhyan@uchc.edu](mailto:turshudzhyan@uchc.edu)

### Abstract

Despite relative effectiveness of current hepatitis B therapies, there is still no curative agents available. The new emerging approaches hold promise to achieve cure and loss of hepatitis B surface antigen. Studies or clinical trials investigating new therapies remain small and either focus on patients with low viral load and without hepatotoxic injury or patients with hepatitis D co-infection, which makes it challenging to assess their effectiveness and side effect profile in hepatitis B population.

**Key Words:** Hepatitis B; Hepatitis B virus; Hepatitis B virus entry inhibitor; Bulevirtide; Transcription activator-like effector nucleases; Zinc-finger nucleases; Clustered regularly interspaced short palindromic repeats-associated 9; Nucleocapsid assembly modulators; Hepatitis B virus transcription inhibitors; Hepatitis B surface antigen release inhibitors

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core Tip:** Hepatitis B could become a curable disease in the near future. As our understanding of pathophysiology of hepatitis B infection advances, more therapeutic targets are becoming available. Many new therapies have only been investigated in small groups of patients with low viral load and without hepatotoxic injury or in patients with hepatitis D co-infection, which makes it difficult to predict efficacy and side effect profile when applied to the population of interest. Larger clinical trials in hepatitis B patients are needed to further investigate the emerging new therapies, so that more patients can safely benefit from them.

**Citation:** Turshudzhyan A, Tadros M. Cautious optimism in anticipation of hepatitis B curative therapies. *World J Virol* 2022; 11(4): 212-215

**URL:** <https://www.wjgnet.com/2220-3249/full/v11/i4/212.htm>

**DOI:** <https://dx.doi.org/10.5501/wjv.v11.i4.212>

## TO THE EDITOR

We read with great pleasure the article by Leowattana *et al*[1] about new emerging therapies in treatment of chronic hepatitis B. They presented a comprehensive review of currently available therapies, pathophysiology of the hepatitis B infection, and developing new therapies. While current therapies, such as nucleosides, are effective in suppressing viral replication and preventing progression of chronic hepatitis to cirrhosis or hepatocellular carcinoma, they are unable to achieve cure from hepatitis B infection. As a result, new therapies are now being investigated that are aimed at a complete cure and loss of hepatitis B surface antigen (HBsAg). Leowattana *et al*[1] presented a comprehensive discussion of developing new therapies, which include agents that inhibit entry of hepatitis B virus (HBV) into hepatocytes, interfere with cccDNA or HBV transcription, alternate nucleocapsid assembly, and prevent HBsAg release from the hepatocytes. The authors are hopeful that given currently available evidence on these emerging therapies, chronic hepatitis B could become a curable disease in the near future. While we share their sentiment and are hopeful for these therapies to be successful in curing hepatitis B infection, we would like to recommend cautious optimism when assessing these new therapeutic agents.

HBV entry inhibitor, bulevirtide, was originally intended to be used for hepatitis D treatment. Wedemeyer *et al*[2] presented results of a phase 2b trial in 2019 which included 60 patients with chronic HBV/ hepatitis D virus (HDV) co-infection. While their results were encouraging, the population under investigation was small and all of the patients had both viruses present, which makes it more difficult to apply these results to patients with HBV infection alone. Wedemeyer *et al*[2] documented increased bile acid concentration in patients on bulevirtide and rebound in viral load after therapy discontinuation, which may cause more liver damage. The increase in bile acid concentration while on bulevirtide was also investigated by the Blank *et al*[3] They confirmed increased bile acid concentration associated with bulevirtide without cholestasis, however, their study was limited to 12 healthy volunteers and did not include patients with pre-existing chronic liver disease or with hepatitis B infection, which makes it less applicable to the population of interest. While there are no ongoing clinical trials with hepatitis B patients on bulevirtide, there is phase 3 trial on bulevirtide use in HDV infection which includes 150 adults with HDV infection[4]. It will help reveal long term effects of therapy and help us better understand the adverse events associated with it. The downside of this phase 3 trial is that it is limited to HDV patients. There is still no long-term data on side effect profile of bulevirtide in HBV patients exclusively. We hope there will be new trials to investigate its application in HBV patients.

Gene editing tools such as the transcription activator-like effector nucleases, zinc-finger nucleases, and clustered regularly interspaced short palindromic repeats-associated 9 could be a new exciting therapy option in curing chronic hepatitis B. The authors did a comprehensive review of the available options for gene editing. It is important to note, however, that like with any genetic intervention there is a risk of off-target cleavage[5], so more studies and large clinical trials are needed to investigate this therapeutic option.

Nucleocapsid assembly modulators are another exciting modality reported by Leowattana *et al*[1] but it is another therapy that should be treated with caution until more data from larger clinical trials is available. Zhang *et al*[6] reported that 75% of patients in their study evaluating nucleocapsid assembly modulators experienced elevations in aminotransferases with 4 out of 24 patients requiring to stop therapy and receive glutathione.

HBV transcription inhibitors are another emerging therapy that is currently being investigated. There were two clinical trials evaluating HBV transcription inhibitors in phase II[7,8] and one clinical trial in phase I[9] that were discontinued because of the observed lethal toxicity of the EX1 delivery formulation. More studies are needed to investigate the safety profile of this therapy before it can be considered for clinical application. Another practical consideration with any emerging therapy that requires a viral vector to be delivered into the cells is the risk of pre-existing immunity to vectors or development of host immunity to vectors during treatment, which will ultimately render therapy ineffective[10].

Lastly, HBsAg release inhibitors have been under investigation in various clinical trials. Alanine aminotransferase flares were observed in 90% of patients treated with HBsAg release inhibitors[11,12]. Additionally, because most of the data came from patients with low viral load, safety and efficacy in patients with high viral load is still to be determined. Similar to bulevirtide, there were reports that discontinuation of HBsAg release inhibitors caused viral rebound precipitating liver decompensation in patient with significant chronic liver disease[13].

We commend Leowattana *et al*[1] for their comprehensive review of the emerging new therapies that have the potential to cure chronic hepatitis B. Our goal was to merely add caution to the optimism and hopefully prompt larger clinical trial specific to hepatitis B population, so that more patients can safely benefit from the new therapies in the near future.

## FOOTNOTES

**Author contributions:** Turshudzhyan A wrote the letter; and Tadros M revised the letter.

**Conflict-of-interest statement:** All authors report no relevant conflicts of interest for this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

**Country/Territory of origin:** United States

**ORCID number:** Alla Turshudzhyan 0000-0001-6867-7569; Micheal Tadros 0000-0003-3118-3893.

**S-Editor:** Ma YJ

**L-Editor:** A

**P-Editor:** Ma YJ

## REFERENCES

- 1 **Leowattana W**, Leowattana T. Chronic hepatitis B: New potential therapeutic drugs target. *World J Virol* 2022; **11**: 57-72 [PMID: 35117971 DOI: 10.5501/wjv.v11.i1.57]
- 2 **Wedemeyer H**, Schöneweis K, Bogomolov PO, Voronkova N, Chulanov V, Stepanova T, B Bremer, L Allweiss, M Dandri, J Burhenne. GS-13-Final results of a multicenter, open-label phase 2 clinical trial (MYR203) to assess safety and efficacy of myrcludex B in cwith PEG-interferon Alpha 2a in patients with chronic HBV/HDV co-infection. *J Hepatol* 2019; **70**: e81 [DOI: 10.1016/S0618-8278(19)30141-0]
- 3 **Blank A**, Eidam A, Haag M, Hohmann N, Burhenne J, Schwab M, van de Graaf S, Meyer MR, Maurer HH, Meier K, Weiss J, Bruckner T, Alexandrov A, Urban S, Mikus G, Haefeli WE. The NTCP-inhibitor Myrcludex B: Effects on Bile Acid Disposition and Tenofovir Pharmacokinetics. *Clin Pharmacol Ther* 2018; **103**: 341-348 [PMID: 28543042 DOI: 10.1002/cpt.744]
- 4 **Gilead Sciences**. Study to Assess Efficacy and Safety of Bulevirtide in Participants With Chronic Hepatitis Delta (CHD). [accessed 2022 May 15]. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: <http://clinicaltrials.gov/show/NCT03852719> ClinicalTrials.gov Identifier: NCT03852719
- 5 **Smith T**, Singh P, Chmielewski KO, Bloom K, Cathomen T, Arbutnot P, Ely A. Improved Specificity and Safety of Anti-Hepatitis B Virus TALENs Using Obligate Heterodimeric FokI Nuclease Domains. *Viruses* 2021; **13** [PMID: 34372550 DOI: 10.3390/v13071344]
- 6 **Zhang H**, Wang F, Zhu X, Chen Y, Chen H, Li X, Wu M, Li C, Liu J, Zhang Y, Ding Y, Niu J. Antiviral Activity and Pharmacokinetics of the Hepatitis B Virus (HBV) Capsid Assembly Modulator GLS4 in Patients With Chronic HBV Infection. *Clin Infect Dis* 2021; **73**: 175-182 [PMID: 32649736 DOI: 10.1093/cid/ciaa961]
- 7 **Arrowhead Pharmaceuticals**. A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection. [accessed 2022 May 15]. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: <http://clinicaltrials.gov/show/NCT02604199> ClinicalTrials.gov Identifier: NCT02604199
- 8 **Arrowhead Pharmaceuticals**. A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Positive, Chronic Hepatitis B Virus Infection. [accessed 2022 May 15]. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: <http://clinicaltrials.gov/show/NCT02604212> ClinicalTrials.gov Identifier: NCT02604212
- 9 **Arrowhead Pharmaceuticals**. A Study of ARC-521 Injection in Normal Adult Volunteers and Patients With Chronic Hepatitis B (CHB). [accessed 2022 May 15]. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: <http://clinicaltrials.gov/show/NCT02797522> ClinicalTrials.gov Identifier: NCT02797522
- 10 **Calcedo R**, Morizono H, Wang L, McCarter R, He J, Jones D, Batshaw ML, Wilson JM. Adeno-associated virus antibody profiles in newborns, children, and adolescents. *Clin Vaccine Immunol* 2011; **18**: 1586-1588 [PMID: 21775517 DOI: 10.1128/CVI.05107-11]
- 11 **Bazinet M**, Pântea V, Placinta G, Moscalu I, Cebotarescu V, Cojuhari L, Jimbei P, Iarovoï L, Smesnoi V, Musteata T, Jucov A, Dittmer U, Krawczyk A, Vaillant A. Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naïve to Nucleos(t)ide Therapy. *Gastroenterology* 2020; **158**: 2180-2194 [PMID: 32147484 DOI: 10.1053/j.gastro.2020.02.058]
- 12 **Al-Mahtab M**, Bazinet M, Vaillant A. Safety and Efficacy of Nucleic Acid Polymers in Monotherapy and Combined with

- Immunotherapy in Treatment-Naive Bangladeshi Patients with HBeAg+ Chronic Hepatitis B Infection. *PLoS One* 2016; **11**: e0156667 [PMID: 27257978 DOI: 10.1371/journal.pone.0156667]
- 13 **Sonneveld MJ**, Gehring AJ, Janssen HLA. Nucleic Acid Polymer Therapy for Hepatitis B Virus: Strong Hepatitis B Surface Antigen Decline But Many Unanswered Questions. *Gastroenterology* 2021; **160**: 966-967 [PMID: 32866506 DOI: 10.1053/j.gastro.2020.06.097]



Published by **Baishideng Publishing Group Inc**  
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-3991568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**Help Desk:** <https://www.f6publishing.com/helpdesk>  
<https://www.wjgnet.com>

